Drug resistance differences among HIV types and subtypes: A growing problem

Future HIV Therapy

Volumn 2, Issue 6, 2008, Pages 579-593

  Soares, Marcelo A ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

AIDS; Antiretroviral; Drug resistance; HIV subtypes; Non B subtypes; Treatment response

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFICACY; DRUG EXPOSURE; GENE MAPPING; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; NONHUMAN; PHENOTYPE; PREVALENCE; REVIEW; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 67149137881     PISSN: 17469600     EISSN: None     Source Type: Journal    
DOI: 10.2217/17469600.2.6.579     Document Type: Review

References (109)

1. Robertson DL, Anderson JP, Bradac JA et al.: HIV-1 nomenclature proposal. Science 288, 55-56 (2000).
2. Hemelaar J, Gouws E, Ghys PD, Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20, W13-W23 (2006).
3. Eholie S, Anglaret X: Commentary: decline of HIV-2 prevalence in West Africa: good news or bad news? Int. J. Epidemiol. 35, 1329-1330 (2006).
4. Burke DS: Recombination in HIV: an important viral evolutionary strategy. Emerg. Infect. Dis. 3, 253-259 (1997).
5. Gao F, Robertson DL, Carruthers CD et al.: A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J. Virol. 72, 5680-5698 (1998).
6. Brown BK, Darden JM, Tovanabutra S et al.: Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01Æ, and CRF02_AG, for the development and assessment of candidate vaccines. J. Virol. 79, 6089-6101 (2005).
7. Arien KK, Abraha A, Quinones-Mateu ME, Kestens L, Vanham G, Arts EJ: The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J. Virol. 79, 8979-8990 (2005).
8. Arien KK, Gali Y, El-Abdellati A, Heyndrick L, Janssens W, Vanham G: Replicative fitness of CCR5-using and CXCR4-using human immunodeficiency virus type 1 biological clones. Virology 347, 65-74 (2006).
9. Gudmundsdotter L, Bernasconi D, Hejdeman B et al.: Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles. Vaccine 26(40), 5182-5187 (2008).
10. Renjifo B, Gilbert P, Chaplin B et al.: Preferential in-utero transmission of HIV-1 subtype C as compared with HIV-1 subtype A or D. AIDS 18, 1629-1636 (2004).
11. Kunanusont C, Foy HM, Kreiss JK et al.: HIV-1 subtypes and male-to-female transmission in Thailand. Lancet 345, 1078-1083 (1995).
12. Kiwanuka N, Laeyendecker O, Robb M et al.: Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J. Infect. Dis. 197, 707-713 (2008).
13. Rangsin R, Piyaraj P, Sirisanthana T, Sirisopana N, Short O, Nelson KE: The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up. AIDS 21(Suppl. 6), S39-S46 (2007).
14. Gottesman BS, Grossman Z, Lorber M et al.: Comparative performance of the Amplicor HIV-1 Monitor Assay versus NucliSens EasyQ in HIV subtype C-infected patients. J. Med. Virol. 78, 883-887 (2006).
15. Chong H, Hong K, Zhang C et al.: Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China. J. Acquir. Immune Defic. Syndr. 47, 535-543 (2008).
16. + T-cell responses with a preference for the predominant circulating clade. J. Acquir. Immune Defic. Syndr. 40, 245-249 (2005).
17. Kantor R, Katzenstein DA, Efron B et al.: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2, e112 (2005).
18. Soares EA, Santos RP, Pellegrini JA, Sprinz E, Tanuri A, Soares MA: Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in southern Brazil. J. Acquir. Immune Defic. Syndr. 34, 520-526 (2003).
19. Soares MA, De Oliveira T, Brindeiro RM et al.: A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil. AIDS 17, 11-21 (2003).
20. Holguin A, Paxinos E, Hertogs K, Womac C, Soriano V: Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J. Clin. Virol. 31, 215-220 (2004).
21. Holguin A, De Arellano ER, Soriano V: Amino acid conservation in the gp41 transmembrane protein and natural polymorphisms associated with enfuvirtide resistance across HIV-1 variants. AIDS Res. Hum. Retroviruses 23, 1067-1074 (2007).
22. Holguin A, Faudon JL, Labernardiere JL, Soriano V: Susceptibility of HIV-1 non-B subtypes and recombinant variants to enfuvirtide. J. Clin. Virol. 38, 176-180 (2007).
23. Gonzalez LM, Brindeiro RM, Tarin M et al.: In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. Antimicrob. Agents Chemother. 47, 2817-2822 (2003).
24. Parkin N, Chappey C, Lam E, Petropoulos C: Reduced susceptibility to protease inhibitors (PI) in the absence of primary PI-resistance-associated mutations. Antivir. Ther. 10, S118 (2005).
25. Fleury HJ, Toni T, Lan NT et al.: Susceptibility to antiretroviral drugs of CRF01Æ, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data. AIDS Res. Hum. Retroviruses 22, 357-366 (2006).
26. Descamps D, Apetrei C, Collin G, Damond F, Simon F, Brun-Vezinet F: Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 12, 1109-1111 (1998).
27. Palmer S, Alaeus A, Albert J, Cox S: Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res. Hum. Retroviruses 14, 157-162 (1998).
28. Tuaillon E, Gueudin M, Lemee V et al.: Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J. Acquir. Immune Defic. Syndr. 37, 1543-1549 (2004).
29. Descamps D, Collin G, Letourneur F et al.: Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J. Virol. 71, 8893-8898 (1997).
30. Colson P, Henry M, Tourres C et al.: Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J. Clin. Microbiol. 42, 570-577 (2004).
31. Desbois D, Roquebert B, Peytavin G et al.: In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob. Agents Chemother. 52, 1545-1548 (2008).
32. Ntemgwa M, Brenner BG, Oliveira M, Moisi D, Wainberg MA: Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob. Agents Chemother. 51, 604-610 (2007).
33. Koh Y, Nakata H, Maeda K et al.: Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47, 3123-3129 (2003).
34. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W: Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. 9, 57-65 (2004).
35. Chinnadurai R, Munch J, Dittmar MT, Kirchhoff F: Inhibition of HIV-1 group M and O isolates by fusion inhibitors. AIDS 19, 1919-1922 (2005).
36. Poveda E, de Mendoza C, Parkin N et al.: Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS 22, 611-616 (2008).
37. Westby M, Smith-Burchnell C, Mori J et al.: Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81, 2359-2371 (2007).
38. Peeters M, Vincent R, Perret JL et al.: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20, 115-121 (1999).
39. Tscherning C, Alaeus A, Fredriksson R et al.: Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 241, 181-188 (1998).
40. Choge I, Cilliers T, Walker P et al.: Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res. Hum. Retroviruses 22, 458-465 (2006).
41. Ndung'u T, Sepako E, McLane MF et al.: HIV-1 subtype C in vitro growth and coreceptor utilization. Virology 347, 247-260 (2006).
42. Huang W, Eshleman SH, Toma J et al.: Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J. Virol. 81, 7885-7893 (2007).
43. Church JD, Huang W, Mwatha A et al.: HIV-1 tropism and survival in vertically infected Ugandan infants. J. Infect. Dis. 197, 1382-1388 (2008).
44. Malet I, Soulie C, Tchertanov L et al.: Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases. J. Med. Virol. 80, 754-761 (2008).
45. Dumans AT, Soares MA, Machado ES et al.: Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance. J. Infect. Dis. 189, 1232-1238 (2004).
46. van de Vijver DA, Wensing AM, Angarano G et al.: The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 41, 352-360 (2006).
47. Resch W, Ziermann R, Parkin N, Gamarnik A, Swanstrom R: Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J. Virol. 76, 8659-8666 (2002).
48. Nijhuis M, Deeks S, Boucher C: Implications of antiretroviral resistance on viral fitness. Curr. Opin. Infect. Dis. 14, 23-28 (2001).
49. Cane PA, de Ruiter A, Rice P, Wiselka M, Fox R, Pillay D: Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom. J. Clin. Microbiol. 39, 2652-2654 (2001).
50. Sugiura W, Matsuda Z, Yokomaku Y et al.: Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 46, 708-715 (2002).
51. Grossman Z, Paxinos EE, Averbuch D et al.: Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob. Agents Chemother. 48, 2159-2165 (2004).
52. Sukasem C, Churdboonchart V, Sukeepaisarncharoen W et al.: Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy. Int. J. Antimicrob. Agents 31, 277-281 (2008).
53. Gonzalez LM, Brindeiro RM, Aguiar RS et al.: Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob. Agents Chemother. 48, 3552-3555 (2004).
54. Holguin A, Sune C, Hamy F, Soriano V, Klimkait T: Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J. Clin. Virol. 36, 264-271 (2006).
55. Ho SK, Coman RM, Bunger JC et al.: Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology 378(2), 272-281 (2008).
56. Coren LV, Thomas JA, Chertova E et al.: Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1. J. Virol. 81, 10047-10054 (2007).
57. de Oliveira T, Engelbrecht S, Janse van Rensburg E et al.: Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness? J. Virol. 77, 9422-9430 (2003).
58. Soares EA, Santos AF, Sousa TM et al.: Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS ONE 2, e730 (2007).
59. Johnson VA, Brun-Vezinet F, Clotet B et al.: Update of the drug resistance mutations in HIV-1: Spring 2008. Top. HIV Med. 16, 62-68 (2008).
60. Abecasis AB, Deforche K, Bacheler LT et al.: Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir. Ther. 11, 581-589 (2006).
61. Clemente JC, Coman RM, Thiaville MM et al.: Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir. Biochemistry 45, 5468-5477 (2006).
62. Brenner BG, Oliveira M, Doualla-Bell F et al.: HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in tell culture. AIDS 20, F9-F13 (2006).
63. Brenner B, Turner D, Oliveira M et al.: A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17, F1-F5 (2003).
64. Gonzalez LM, Aguiar RS, Afonso A et al.: Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations. J. Gen. Virol. 87, 1303-1309 (2006).
65. Eshleman SH, Church JD, Chen S et al.: Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D. J. Acquir. Immune Defic. Syndr. 42, 518-521 (2006).
66. Flys TS, Chen S, Jones DC et al.: Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J. Acquir. Immune Defic. Syndr. 42, 610-613 (2006).
67. Eshleman SH, Guay LA, Wang J et al.: Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J. Acquir. Immune Defic. Syndr. 40, 24-29 (2005).
68. Eshleman SH, Guay LA, Mwatha A et al.: Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network for Prevention Trials 012. J. Acquir. Immune Defic. Syndr. 39, 593-597 (2005).
69. Eshleman SH, Hoover DR, Chen S et al.: Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 19, 2167-2169 (2005).
70. Church JD, Hudelson SE, Guay LA et al.: HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D. AIDS Res. Hum. Retroviruses 23, 764-768 (2007).
71. Eshleman SH, Jones D, Galovich J et al.: Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations. AIDS Res. Hum. Retroviruses 22, 289-293 (2006).
72. Flys TS, Donnell D, Mwatha A et al.: Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J. Infect. Dis. 195, 711-715 (2007).
73. Johnson JA, Li JF, Morris L et al.: Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J. Infect. Dis. 192, 16-23 (2005).
74. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L: Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 20, 995-1002 (2006).
75. Kuhn L, Sinkala M, Kankasa MP, Kasonde P, Thea DM, Aldrovandi GM: Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission. J. Acquir. Immune Defic. Syndr. 42, 260-262 (2006).
76. Lee EJ, Kantor R, Zijenah L et al.: Breast-milk shedding of drug-resistant HIV-I subtype C in women exposed to single-dose nevirapine. J. Infect. Dis. 192, 1260-1264 (2005).
77. Toni TD, Masquelier B, Lazaro E et al.: Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Cote d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission. AIDS Res. Hum. Retroviruses 21, 1031-1034 (2005).
78. Van Laethem K, De Luca A, Antinori A, CingolaniA, Perna CF, Van damme AM: A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir. Ther. 7, 123-129 (2002).
79. Shafer RW, Jung DR, Betts BJ: Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nat. Med. 6, 1290-1292 (2000).
80. Brun-Vezinet F, Descamps D, Ruffault A et al.: Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 17, 1795-1802 (2003).
81. Beerenwinkel N, Daumer M, Oette M et al.: Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res. 31, 3850-3855 (2003).
82. Wolf K, Walter H, Beerenwinkel N et al.: Tenofovir resistance and resensitization. Antimicrob. Agents Chemother. 47, 3478-3484 (2003).
83. Ly JK, Margot NA, MacArthur HL, Hung M, Miller MD, White KL: The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V. Antivir. Chem. Chemother. 18, 307-316 (2007).
84. Deforche K, Camacho R, Grossman Z et al.: Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. Infect. Genet. Evol. 7, 382-390 (2007).
85. Deforche K, Silander T, Camacho R et al.: Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance. Bioinformatics 22, 2975-2979 (2006).
86. Kijak GH, Rubio AE, Pampuro SE et al.: Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms. HIV Med. 4, 72-78 (2003).
87. Ravela J, Betts BJ, Brun-Vezinet F et al.: HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J. Acquir. Immune Defic. Syndr. 33, 8-14 (2003).
88. Snoeck J, Kantor R, Shafer RW et al.: Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob. Agents Chemother. 50, 694-701 (2006).
89. Vergne L, Snoeck J, Aghokeng A et al.: Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. FEMS Immunol. Med. Microbiol. 46, 53-62 (2006).
90. Frater AJ, Beardall A, Ariyoshi K et al.: Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 15, 1493-1502 (2001).
91. Frater AJ, Dunn DT, Beardall AJ et al.: Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 16, 1139-1146 (2002).
92. Bocket L, Cheret A, Deuffic-Burban S et al.: Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir. Ther. 10, 247-254 (2005).
93. Alexander CS, Montessori V, Wynhoven B et al.: Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir. Ther. 7, 31-35 (2002).
94. Garrido C, Zahonero N, Fernandes D et al.: Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J. Antimicrob. Chemother. 61, 694-698 (2008).
95. De Wit S, Boulme R, Poll B, Schmit JC, Clumeck N: Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients. AIDS 18, 2330-2331 (2004).
96. Atlas A, Granath F, Lindstrom A, Lidman K, Lindback S, Alaeus A: Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy. AIDS Res. Hum. Retroviruses 21, 221-227 (2005).
97. Ruelle J, Roman F, Vandenbroucke AT et al.: Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect. Dis. 8, 21 (2008).
98. Aggarwall, Smith M, Tatt ID et al.: Evidence for onward transmission of HIV-1 non-B subtype strains in the United Kingdom. J. Acquir. Immune Defic. Syndr. 41, 201-209 (2006).
99. Baldanti F, Paolucci S, Ravasi G et al.: Changes in circulation of B and non-B HIV strains: spotlight on a reference centre for infectious diseases in Northern Italy. J. Med. Virol. 80, 947-952 (2008).
100. Falkensammer B, Doerler M, Kessler HH et al.: Subtype and genotypic resistance analysis of HIV-1 infected patients in Austria. Wien. Klin. Wochenschr. 119, 181-185 (2007).
101. Holguin A, de Mulder M, Yebra G, Lopez M, Soriano V: Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards and immigrants in Spain. Curr. HIV Res. 6, 327-334 (2008).
102. Pillonel J, Barin F, Laperche S et al.: Human immunodeficiency virus type 1 incidence among blood donors in France, 1992 through 2006: use of an immunoassay to identify recent infections. Transfusion 48, 1567-1575 (2008).
103. Snoeck J, Van Laethem K, Hermans P et al.: Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001. J. Acquir. Immune Defic. Syndr. 35, 279-285 (2004).
104. Yirrell DL, Shaw L, Campbell E, Burns SM, Cameron SO, Goldberg D: HIV subtypes in Scotland, 2000-2006. Epidemiol. Infect. 136, 1069-1075 (2008).
105. Lin HH, Gaschen BK, Collie M et al.: Genetic characterization of diverse HIV-1 strains in an immigrant population living in New York City. J. Acquir. Immune Defic. Syndr. 41, 399-404 (2006).
106. Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK: Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance. J. Virol. 81, 6837-6845 (2007).
107. Nikolenko GN, Delviks-Frankenberry KA, Palmer S et al.: Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc. Natl Acad. Sci. USA 104, 317-322 (2007).
108. Nikolenko GN, Palmer S, Maldarelli F, Mellors JW, Coffin JM, Pathak VK: Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc. Natl Acad. Sci. USA 102, 2093-2098 (2005).
109. Santos AF, Lengruber RB, Soares EA et al.: Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS ONE 3, e1781 (2008).